Canada Exercises Increased Option for 20 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
23 September 2020 - 2:22AM
Business Wire
Canadian Government maintains option for an
additional 36 million doses
Agreement underscores growing global confidence
in mRNA platform and progress of Phase 3 study of mRNA-1273
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines to create a new
generation of transformative medicines for patients, today
announced the Canadian Government has increased its confirmed order
commitment to 20 million doses of Moderna’s vaccine candidate
against COVID-19, mRNA-1273.
This updated agreement comes as Moderna’s Phase 3 COVE study has
enrolled more than 75% of its participants, 11,879 of whom have
received their second vaccination as of September 18, 2020. To
provide additional transparency in the context of the pandemic, the
Company also made the complete, unredacted protocol for the Phase 3
trial of mRNA-1273 available online on Thursday, September 17.
“We appreciate the confidence in Moderna’s mRNA platform and the
progress we are making with mRNA-1273, as demonstrated by the
increased order from the Canadian government today,” said Stephane
Bancel, Moderna’s Chief Executive Officer. “This support, along
with that of our stakeholders, drives us forward as we scale-up our
global manufacturing and distribution network.”
Moderna remains on track to be able to deliver up to 56 million
doses of its COVID-19 vaccine to help protect Canadians beginning
in 2021. The Canadian vaccine supply will be sourced from Moderna’s
European production capacity with its strategic manufacturing
partner Lonza of Switzerland, and ROVI of Spain for fill-finish
services.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a
new class of transformative medicines for patients. mRNA medicines
are designed to direct the body’s cells to produce intracellular,
membrane or secreted proteins that can have a therapeutic or
preventive benefit and have the potential to address a broad
spectrum of diseases. The company’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing Moderna the capability to pursue in
parallel a robust pipeline of new development candidates. Moderna
is developing therapeutics and vaccines for infectious diseases,
immuno-oncology, rare diseases and cardiovascular diseases,
independently and with strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca PLC
and Merck & Co., Inc., as well as the Defense Advanced Research
Projects Agency (DARPA), an agency of the U.S. Department of
Defense, and the Biomedical Advanced Research and Development
Authority (BARDA), a division of the Office of the Assistant
Secretary for Preparedness and Response (ASPR) within the U.S.
Department of Health and Human Services (HHS). Moderna has been
named a top biopharmaceutical employer by Science for the past five
years. To learn more, visit www.modernatx.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including regarding the Company’s development of
a potential vaccine against the novel coronavirus, the potential
for mRNA-1273 to prevent COVID-19 disease and slow the spread of
SARS-CoV-2, plans for expansion into the Canadian market, the
supply of mRNA-1273 to the Canadian government, and plans for the
manufacturing and distribution of mRNA-1273. In some cases,
forward-looking statements can be identified by terminology such as
“will,” “may,” “should,” “could”, “expects,” “intends,” “plans,”
“aims,” “anticipates,” “believes,” “estimates,” “predicts,”
“potential,” “continue,” or the negative of these terms or other
comparable terminology, although not all forward-looking statements
contain these words. The forward-looking statements in this press
release are neither promises nor guarantees, and you should not
place undue reliance on these forward-looking statements because
they involve known and unknown risks, uncertainties, and other
factors, many of which are beyond Moderna’s control and which could
cause actual results to differ materially from those expressed or
implied by these forward-looking statements. These risks,
uncertainties, and other factors include, among others: the fact
that there has never been a commercial product utilizing mRNA
technology approved for use; the fact that the rapid response
technology in use by Moderna is still being developed and
implemented; the fact that the safety and efficacy of mRNA-1273 has
not yet been established; potential adverse impacts due to the
global COVID-19 pandemic such as delays in regulatory review,
manufacturing and clinical trials, supply chain interruptions,
adverse effects on healthcare systems and disruption of the global
economy; and those other risks and uncertainties described under
the heading “Risk Factors” in Moderna’s most recent Quarterly
Report on Form 10-Q filed with the U.S. Securities and Exchange
Commission (SEC) and in subsequent filings made by Moderna with the
SEC, which are available on the SEC’s website at www.sec.gov.
Except as required by law, Moderna disclaims any intention or
responsibility for updating or revising any forward-looking
statements contained in this press release in the event of new
information, future developments or otherwise. These
forward-looking statements are based on Moderna’s current
expectations and speak only as of the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200922005848/en/
Canadian Media Enquiries
Paul Monlezun +1 613-222-7184
paul.monlezun@publicaffairsadvisors.com
Moderna Contacts
Media: Colleen Hussey Senior Manager, Corporate Communications
617-335-1374 Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Head of Investor Relations
617-209-5834 Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2024 to May 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From May 2023 to May 2024